Company news: MedVantx, Boehringer Ingelheim

Share this article:

MedVantx rolled out the first samples of generic atorvastatin to its network, which includes the 3,500 doctors in eight states. The 30-day samples will be distributed through the company's MedStart Connect program, which MedVantx said “is a new tool to help physicians transition to accountable care and medical home delivery models, and provides convenience and affordability without ever having to go to a pharmacy.” Atorvastatin was, until November, available only as branded Lipitor, but multiple generics have since entered the market and prices have plummeted. US physicians wrote more than 45 million prescriptions for the drug in 2011.

Boehringer Ingelheim launched Combivent Respimat Inhalation Spray for COPD. It's a new delivery mechanism for the dual-action drug, comprised of ipratropium bromide and albuterol, and does the last-generation Combivent MDI (Metered Dose Inhaler) one better by reducing the number of inhalations per dose from two to one and giving patients 30 days treatment per use compared with 25 days for Combivent MDI, “so that patients may require two less inhalers over the course of a year,” the company said.  

Share this article:

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.